Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +42.18%
#2 0G 0G +27.29%
#3 Pons Pons +26.97%
#4 SAFEcoin SAFEcoin +26.87%
#5 Zora Zora +25.96%
#6 Seeker Seeker +23.15%
#7 VVS Finance VVS Finance +21.62%
#8 Full Moon Full Moon +17.50%
#9 ADO Protocol ADO Protocol +16.58%
#10 Apertum Apertum +15.82%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Settings
Language
ENGLISH
Currency
USD
Theme
Hansa Biopharma AB (publ) Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ)

HNSA
Rank in Stocks #13430
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing... Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Share Price
$4.91
Market Cap
$489.47M
Change (1 day)
-1.35%
Change (1 year)
43.50%
Country
SE
Trade Hansa Biopharma AB (publ) (HNSA)

Category

Healthcare
P/E ratio for Hansa Biopharma AB (publ) (HNSA)
P/E ratio as of 2026 TTM: 0
According to Hansa Biopharma AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Hansa Biopharma AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.